Gilead Sciences, Inc.

Medarex Inc.

Novartis Ag

Skylark Bioscience LLC

Axys Pharmaceuticals, Inc.

Oliver L Saunders

Jay P Parrish

Choung U Kim

Howard P Ng

Guoxian Wu

Lijun Zhang

Richard L Mackman

Aesop Cho

Thomas Butler

Danny P C McGee

Constantine G Boojamra

David Sperandio

Valeri Martichonok

Dustin S Siegel

Hon Chung Hui

Michael Sangi

Hai Yang

Martijn Fenaux

Kerim Babaoglu

Fumiaki Yokokawa

Zhi-Hong Li

Eugene J Eisenberg

Weidong Zhong

Sanjeev Gangwar

David J King

Irina Astafieva

Thomas Jay Lobl

Jimmie L Moore

Zhihong Li

Sharon Elaine Boyd

Zachary Kevin Sweeney

James Ming Chen

Samuel E Metobo

Jie Xu

Xiaodong Lin

Alan X Huang

Benjamin R Graetz

Jason K Perry

Sampath-Kumar Anandan

Andrew W Waltman

Liang Mao

Virender Singh Aulakh

John O Link

Sheila M Zipfel

Kuei-Ying Lin

David A Oare

John W Patterson

Sundaramoorthi Swaminathan

Geoffrey T Yarranton

Danny Pc McGee

Arnold J Martelli

Danny P Mcgee

Geoffrey Thomas Yarranton

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions associated with activation of AMP-activated protein kinase, wherein the compound is of Formula (I): as described herein, including pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such compounds, as well as methods to use these compositions for treating indications including cancer, diabetes, ischemic injury, obesity, hyperlipidemia, and cardiac conditions.

AMP-activated protein kinase activating compounds and uses thereof

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions such as muscle disorders such as polymyositis, dermatomyositis, muscular dystrophy, myasthenia gravis, amyotrophic lateral sclerosis, rhabdomyolysis, and cardiomyopathy, brain disorders including Alzheimer's, stroke, cerebral atrophy, traumatic brain injury, and dementia, aging, diabetes, and cancer, using compounds of Formula (I): as described herein, including pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising these compounds.

Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I. 

Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs

The present invention provides a compound of Formula (I) or a salt thereof; 

Alkynyl nucleoside analogs as inhibitors of human rhinovirus

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.

The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

Pyrazolo[1,5-A]pyrimidines for antiviral treatment

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

1'-substituted carba-nucleoside analogs for antiviral treatment

The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R, R, R, R, Rand Z are defined herein, which is a 2'-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.

2'-ethynyl nucleoside derivatives for treatment of viral infections

The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R, R, R, R, Rand Z are as defined herein, which is a 2'-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue fever, yellow fever, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.

2'-Ethynyl nucleoside derivatives for treatment of viral infections

The invention provides compounds of Formula I or Formula II: 

Pyrazolo[1,5-a]pyrimidines for antiviral treatment

The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically acceptable salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals (e.g. humans). 

Nucleoside analogs for antiviral treatment

Growing community of inventors

San Mateo, CA, United States of America

Oliver L Saunders